Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy

Endocrine Journal

Volumn 57, Issue 10, 2010, Pages 853-861

  Tachibana, Seigo ^a   Murakami, Tsukasa ^a   Noguchi, Hitoshi ^a   Noguchi, Yasushi ^a   Nakashima, Akiko ^a   Ohyabu, Yufuko ^b   Noguchi, Shiro ^a  

^a Noguchi Thyroid Clinic and Hospital Foundation   (Japan)

^b Kitahama eye clinic   (Japan)

Author keywords

CAS; Glucocorticoid; Graves' ophthalmopathy; Immunosuppressive therapy; Orbital MRI

Indexed keywords

ANTITHYROID AGENT; GLUCOCORTICOID; LEVOTHYROXINE; METHYLPREDNISOLONE; POTASSIUM IODIDE; PREDNISOLONE; RADIOACTIVE IODINE;

ADULT; ARTICLE; CASE STUDY; CLINICAL ACTIVITY SCORE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG DOSE SEQUENCE; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOMETRY; EXTRAOCULAR MUSCLE; EYE EXAMINATION; EYELID; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT; PREDICTION; PROSPECTIVE STUDY; RELAXATION TIME; REPEATED DRUG DOSE; RETROBULBAR IRRADIATION; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOSUPPRESSION; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MIDDLE AGED; OCULOMOTOR MUSCLES; PREDNISOLONE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78649378310     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-156     Document Type: Article

References (20)

1. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158: 273-285.
2. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R (1989) Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 73: 639-644.
3. Dickinson AJ, Perros P (2001) Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 55: 283-303.
4. Hiromatsu Y, Kojima K, Ishisaka N, Tanaka K, Sato M, Nonaka K, Nishimura H, Nishida H (1992) Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 2: 299-305.
5. Kirsch E, Hammer B, von Arx G (2009) Graves' orbitopathy: current imaging procedures. Swiss Med Wkly 139: 618-623.
6. Ohnishi T, Noguchi S, Murakami N, Tajiri J, Harao M, Kawamoto H, Hoshi H, Jinnouchi S, Futami S, Nagamachi S, Watanabe K (1994) Extraocular muscles in Graves ophthalmopathy: usefulness of T2 relaxation time measurements. Radiology 190: 857-862.
7. Yokoyama N, Nagataki S, Uetani M, Ashizawa K, Eguchi K (2002) Role of magnetic resonance imaging in the assessment of disease activity in thyroid-associated ophthalmopathy. Thyroid 12: 223-227.
8. Gerding MN, Prummel MF, Wiersinga WM (2000) Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol (Oxf) 52: 641-646.
9. Gerding MN, van der Zant FM, van Royen EA, Koornneef L, Krenning EP, Wiersinga WM, Prummel MF (1999) Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 50: 373-379.
10. Donaldson SS, Bagshaw MA, Kriss JP (1973) Supervoltage orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 37: 276-285.
11. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 47: 9-14.
12. Kirsch EC, Kaim AH, De Oliveira MG, von Arx G (2010) Correlation of signal intensity ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of therapy response in Graves' orbitopathy-a pilot study at 1.5 T. Neuroradiology 52: 91-97.
13. Mayer E, Herdman G, Burnett C, Kabala J, Goddard P, Potts MJ (2001) Serial STIR magnetic resonance imaging correlates with clinical score of activity in thyroid disease. Eye (Lond) 15: 313-318.
14. Mayer EJ, Fox DL, Herdman G, Hsuan J, Kabala J, Goddard P, Potts MJ, Lee RW (2005) Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol 56: 20-24.
15. Just M, Kahaly G, Higer HP, Rosler HP, Kutzner J, Beyer J, Thelen M (1991) Graves ophthalmopathy: role of MR imaging in radiation therapy. Radiology 179: 187-190.
16. Galuska L, Leovey A, Szucs-Farkas Z, Szabados L, Garai I, Berta A, Balazs E, Varga J, Nagy EV (2005) Imaging of disease activity in Graves' orbitopathy with different methods: comparison of (99m)Tc-DTPA and (99m)Tc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores. Nucl Med Commun 26: 407-414.
17. Saber E, McDonnell J, Zimmermann KM, Yugar JE, Feldon SE (1996) Extraocular muscle changes in experimental orbital venous stasis: some similarities to Graves' orbitopathy. Graefes Arch Clin Exp Ophthalmol 234: 331-336.
18. de Juan E, Jr., Hurley DP, Sapira JD (1980) Racial differences in normal values of proptosis. Arch Intern Med 140: 1230-1231.
19. Tellez M, Cooper J, Edmonds C (1992) Graves' ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) 36: 291-294.
20. Tsai CC, Kau HC, Kao SC, Hsu WM (2006) Exophthalmos of patients with Graves' disease in Chinese of Taiwan. Eye (Lond) 20: 569-573.